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Abstract
The discovery of a new series of compounds that are potent, selective 5-HT2C receptor agonists is 
described herein as we continue our efforts to optimize the 2-phenylcyclopropylmethylamine 
scaffold. Modifications focused on the alkoxyl substituent present on the aromatic ring led to the 
identification of improved ligands with better potency at the 5-HT2C receptor and excellent 
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selectivity against the 5-HT2A and 5-HT2B receptors. ADMET studies coupled with a behavioral 
test using the amphetamine-induced hyperactivity model identified four compounds possessing 
drug-like profiles and having antipsychotic properties. Compound (+)-16b, which displayed an 
EC50 of 4.2 nM at 5-HT2C, no activity at 5-HT2B, and an 89-fold selectivity against 5-HT2A, is 
one of the most potent and selective 5-HT2C agonists reported to date. The likely binding mode of 
this series of compounds to the 5-HT2C receptor was also investigated in a modeling study, using 
optimized models incorporating the structures of β2-adrenergic receptor and 5-HT2B receptor.
Graphical Abstract
INTRODUCTION
Serotonin or 5-hydroxytryptamine (5-HT) is a major neurotransmitter that is primarily found 
in the gastrointestinal tract, platelets, and the central nervous system (CNS). It is believed to 
be involved in the regulation of a variety of physiological functions such as intestinal 
movements, mood, cognition, and appetite.1 These functions are mediated through serotonin 
receptors, which belong to the G-protein coupled receptor (GPCR) superfamily and are 
composed of seven subfamilies (5-HT1–7) and 14 isoforms.2
Recently, the serotonin 2C (5-HT2C) receptor has been shown to be a promising drug target 
for the treatment of a variety of CNS disorders, including obesity and mental disorders such 
as schizophrenia, depression, and anxiety.3–7 One of the many advantages of the 5-HT2C 
receptor as a CNS drug target stems from the fact that it is found almost exclusively in the 
CNS,8,9 and thus compounds that selectively activate this receptor should have limited 
impact on peripheral tissues. However, the activation of two other closely related 5-HT2 
subtypes, namely the 5-HT2A and 5-HT2B receptors, has been reported to be associated with 
hallucinations and cardiac valvulopathy, respectively.10 Therefore, the identification of 
ligands possessing exquisite selectivity against the 5-HT2A and 5-HT2B receptors is a key 
criterion for the therapeutic advancement of 5-HT2C agonists. The achievement of this goal 
has been challenging due to the high conservation of molecular determinants involved in 
ligand recognition within this subfamily of receptors.11
Currently, there are a number of 5-HT2C agonists (Figure 1, 1–6) generated for potential 
therapeutic uses or as chemical tools for the study of the biological roles of 5-HT2C receptor. 
Among them, lorcaserin (Belviq, 1) was approved by the FDA in 2012 for the treatment of 
obesity. Although it was reported to have 100-fold selectivity for 5-HT2C relative to the 5-
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HT2B subtype, lorcaserin possesses full agonist activity at 5-HT2B (EC50 = 943 ± 90 nM, 
Emax = 100%).12 Hence, it is not surprising that lorcaserin was found to cause a higher 
incidence of cardiac valve disorders in clinical trials compared to the placebo group.13
Vabicaserin (SCA-136, 2), by targeting 5-HT2C receptors (EC50 = 8 nM, Emax = 100%), was 
tested in clinical trials for the treatment of schizophrenia;14 however, it displayed moderate 
efficacy on 5-HT2B receptors (Emax = 50%) and good potency (EC50 = 12 or 102 nM 
depending on receptor densities).15 WAY-163909 (3), an analogue of vabicaserin, was shown 
to have selectivity toward 5-HT2C (EC50 = 8 nM; Emax = 90%) while possessing no agonist 
activity at 5-HT2A and weak efficacy at 5-HT2B receptors (Emax = 40%); it has proven to 
have good preclinical antipsychotic-like activity in several animal models.16 Compound 
CP-809,101 (4) is one of the most selective and potent 5-HT2C (EC50 = 0.11 nM, Emax = 
93%) ligands developed, with about 600-fold 5-HT2C selectivity against 5-HT2B. However, 
it is still relatively potent at 5-HT2B (EC50 = 65.3 nM, Emax = 57%).17 Because of the 
genotoxicity of this compound, it could not be advanced to clinical evaluation.18 
Nonetheless, CP-809,101 has structural similarities to mCPP (5) and MK-212 (6), two 
compounds discovered decades ago and used as tools for the pharmacological study of 5-
HT2C receptors.19,20
In our own research, we focused on compounds that possessed the 2-
phenylcyclopropylmethylamine scaffold (7) to develop selective 5-HT2C agonists. This 
particular scaffold was derived from an initial high throughput screening (HTS) screening 
campaign in which tranylcypromine was identified as a hit as described in an earlier 
publication.21 Rational drug design principles coupled with the evolution of a body of 
structure–activity relationships (SARs) led to the identification of compounds possessing a 
2-cyclopropylmethoxy group at position 2, as illustrated by compounds 8, 9, and 10 (Figure 
2). Compound 8, which possesses a fluorine substitution at position 5 of the benzene ring, 
showed good potency on the 5-HT2C receptor (EC50 = 21 nM), with only moderate 
selectivity for 5-HT2B (EC50 = 289 nM).22 The replacement of the fluorine atom with a 
hydroxyl group, as in compound 9, led to the enhancement of both potency and selectivity, 
but the bioavailability of compound 9 was found to be too low in a later study (F = 3.2% in 
mice, unpublished data). Compound 10, with no substitution at the same position, showed 
good potency as a partial agonist (EC50 = 55 nM, Emax = 61%), with great selectivity against 
both 5-HT2A and 5-HT2B.23 Considering the needs of more selective and potent 5-HT2C 
agonists for the validation of their therapeutic potential in the treatment of various illnesses 
associated with 5-HT2C, we conducted a new round of lead optimization on this promising 
scaffold. The chemical synthesis and SAR results obtained for the new compounds are 
reported herein, together with a rodent behavioral test and a homology modeling study. 
These new analogues provide improvements compared to previous compounds.
RESULTS
Design and Synthesis of 5-Chlorine Substituted Compounds
Prior SAR studies showed that compounds with an alkoxyl group at position 2 provided the 
most favorable 5-HT2C agonism and selectivity toward 5-HT2A and 5-HT2B, and thus this 
substitution pattern was therefore retained in further rounds of structural modifications. 
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Through a careful structural analysis of known 5-HT2C agonists as well as other CNS drugs, 
it is apparent that a chlorine atom represents one of the most frequently used substituents for 
aromatic rings. This observation is exemplified by mCPP, MK-212, and lorcaserin, all of 
which contain a chlorine substituent located at a position meta to the nitrogen-containing 
group. Thus, we introduced the chlorine atom as the substituent at position 5, and further 
optimization of the alkyl ether group was conducted to improve 5-HT2C potency as well as 
selectivity over both 5-HT2A and 5-HT2B.
As depicted in Scheme 1, the synthesis of the 5-chlorine containing analogues started from 
the corresponding phenol 11, which was prepared using methods similar to those reported 
previously by us for the 5-bromo analogue.23 The cyclopropane ring of 11 was prepared in 
its trans configuration, as this stereochemistry has proven to be favored in our previous SAR 
studies. The ether derivatives 12a–12n were prepared either by a standard Williamson ether 
synthesis with an alkyl halide or by use of the Mitsunobu reaction with the appropriate 
alcohol (for details of the synthesis of 12a–12n, see Supporting Information, Table S1). 
Chiral separations of 12a–12n were achieved with preparative chiral HPLC and the 
corresponding (+)- and (−)-enantiomers were then subjected to Boc deprotection reactions to 
provide both (−)- and (+)-enantiomers of compounds 13a–13n as their HCl or TFA salts. 
The absolute configurations of the enantiomers were assigned from the measured optical 
rotations coupled with the stereochemical correlations reported previously by us.21
On the basis of the SAR data from our previous work, we hypothesized that the alkoxyl 
substituents at position 2 on the benzene ring might be accommodated within a hydrophobic 
cavity, which could vary in size among the 5-HT2C, 5-HT2A, and 5-HT2B receptors. This 
cavity might be slightly larger for the 5-HT2C receptors compared to the 5-HT2A and 5-
HT2B receptors based on the observation that (1) small groups attached to position 2 
displayed good activity at all three subtypes (less selectivity) and (2) increasing the size of 
the substituent resulted in a decrease in activity at 5-HT2A and 5-HT2B while retaining good 
activity at 5-HT2C. Accordingly, we believed that by achieving a proper balance of size and 
lipophilicity, we should be able to identify more potent 5-HT2C agonists with improved 
selectivity against the 5-HT2A and 5-HT2B subtypes.
To explore this assumption, compounds with varied alkoxyl groups were designed and 
synthesized. Functional activities at the 5-HT2C, 5-HT2A, and 5-HT2B receptors were 
determined, and physiochemical properties related to possible CNS penetration such as the 
CLogP and LogBB values were calculated using the ACD Percepta program. These values 
are listed in Table 1. Generally, the (+)-isomers of all new compounds were found to be 
more potent than the (−)-isomers, which is consistent with our previously published SAR 
data.23 As evidenced by compounds 13a, 13b, and 13c, potency at the 5-HT2C receptor 
decreases with elongation of the alkyl chain, while selectivity over 5-HT2B and 5-HT2A 
improves. n-Propyl substitution as in compound (+)-13b was favored with respect to both 
activity and selectivity. The change from an n-propyl group to an isopropyl group gave 
compound (+)-13d that has similar 5-HT2C activity but decreased selectivity against 5-HT2B 
(33-fold selectivity for (+)-13b vs 11-fold selectivity for (+)-13d). The cyclopropylmethoxy 
group was the preferred ether substituent at position 2 of the benzene ring based on our 
previous findings;22,23 however, the use of this group as found in compound (+)-13e 
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afforded only a moderate potency at 5-HT2C receptors (EC50 = 251 nM, Emax = 75%). 
Incorporation of an additional heteroatom such as oxygen or sulfur into the ether appendage, 
as exemplified by compounds 13f and 13g, led to a large reduction in 5-HT2C activity as 
well as a predicted decrease in blood-brain barrier (BBB) penetration based upon the 
calculated LogBB values.
Unsaturated alkyl groups, such as allyl and propargyl, were preferred both for their potency 
and selectivity, as revealed by compounds (+)-13h and (+)-13i. (+)-13h showed a 
moderately good pharmacological profile, with 60 nM potency at 5-HT2C, 37-fold 
selectivity against 5-HT2B (2211 nM), and no activity at 5-HT2A. Furthermore, good 
physiochemical properties were predicted for this compound. Similar potency and selectivity 
was observed for (+)-13i as well, however, it was predicted to have low brain penetration, as 
indicated by its LogBB value of −0.43. Allyl ethers bearing small modifications were also 
explored, as exemplified by compounds 13j and 13k. The presence of a fluorine substituent 
as in compound (+)-13j resulted in a 2-fold reduction in 5-HT2C activity compared to 
(+)-13h (133 vs 60 nM) while maintaining the same general selectivity profile against 5-
HT2B and 5-HT2A. The presence of the fluorine atom might provide some advantage in 
terms of pharmacokinetics due to the possibility of reducing oxidative metabolism of the 
double bond. By adding an additional methyl group to the position 2 of the allyl appendage 
as in compound (+)-13k, the potency was reduced to 212 nM at the 5-HT2C receptors while 
its selectivity also decreased in comparison to compounds 13h and 13j.
The 2-fluoroethyl ether analogue (+)-13l displayed 32 nM potency at 5-HT2C and good 
selectivity against both 5-HT2A and 5-HT2B. Upon introducing one additional fluorine atom 
into the molecule by way of a 2,2-difluoroethyl appendage as in analogue 13m, a 3-fold 
decrease in activity at 5-HT2C (EC50 = 91 nM vs 32 nM) was observed. This drop in activity 
may result from either increased steric hindrance or electronic effects. Additionally, the 
incorporation of a 3-fluoropropyl ether appendage as in (+)-13n also led to a drop in potency 
(EC50 = 206 nM) compared to the simple unsubstituted propyl derivative (+)-13b, although 
(+)-13n possessed a reasonably good selectivity profile.
On the basis of the data from Table 1, compounds (+)-13h and (+)-13l represent the best 
ligands among this series of compounds, but they are about 10-fold less potent than 
lorcaserin, which shows an EC50 value of 3.6 nM on 5-HT2C in the functional calcium-based 
assay. Although lorcaserin displays around 100-fold selectivity over both 5-HT2B and 5-
HT2A, it acts as a full or partial agonist at both receptors. As such, lorcaserin has potential 
side effect issues as discussed previously. Compounds (+)-13h and (+)-13l, along with 
(+)-13j, which might provide better PK properties due to the presence of the fluorine 
substitution, were advanced to in vitro ADMET studies.
ADMET Studies
Compounds (+)-13h, (+)-13j, and (+)-13l were evaluated for selected in vitro ADME 
properties and toxicity profiles (Table 2). In Caco-2 permeability studies, compounds 
(+)-13h, (+)-13j, and (+)-13l displayed greater than 35 × 10−6 cm/s A–B permeability in pH 
7.4 buffer solution, and A–B/B–A ratios of 3.6, 3.5, and 2.0, respectively. When incubated 
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with human and CD-1 mouse liver microsomes, all three compounds retained reasonably 
good stability, with more than 50% compound remaining after 1 h. Interestingly, although 
compound (+)-13h and (+)-13j displayed similar stability in the mouse liver microsomes test 
(60% vs 62%), (+)-13j had much better stability in the human microsomes study compared 
to (+)-13h (80% vs 52%), which could be due to the presence of the fluorine substitution as 
expected. Relatively low human plasma protein binding (57–75%) was measured for 
compounds (+)-13h, (+)-13j, and (+)-13l, which was expected based on their good CLogP 
values (between 2 and 3 as in Table 1), as Log P is an important indicator that determines 
protein binding properties.24
Human cytochrome P450 (CYP) enzyme inhibition studies were conducted using the five 
most important isoforms, 3A, 2D6, 2C9, 2C19, and 2B6, at compound concentrations of 10 
µM. Similar profiles were observed for all three compounds, with low inhibition of CYP3A 
and CYP2C19 and relatively higher inhibition of the other three isoforms (>50%). 
Compound (+)-13j shows a slightly better profile compared to (+)-13h, which indicates 
another benefit of the fluorine substituent. In the hERG inhibition test with the automated 
patch-clamp assay, moderate inhibition was observed with compounds (+)-13j and (+)-13l, 
while (+)-13h was found to have an IC50 of 0.27 µM. The Ames test was also conducted to 
preclude any mutagenic potential of these compounds; all three compounds showed negative 
results. Because of the high hERG activity of (+)-13h, this compound was not further 
evaluated. Thus, only compounds (+)-13j and (+)-13l were submitted to the in vivo brain 
penetration studies.
Brain penetration studies of (+)-13j and (+)-13l were conducted with CD1 mice, and the 
results are listed in Table 3. Excellent brain penetration was observed for both compounds, 
with brain concentrations of greater than 50 µM achieved at a dose of 10 mg/kg (ip) and 
with brain/plasma ratios over 10 at both time-points (0.5 and 2 h). The excellent brain 
penetration for these two compounds coupled with low plasma protein binding should 
ensure optimal CNS distribution of both compounds. The lower plasma concentrations 
would also help to mitigate possible cardiac toxicity related to hERG inhibition observed in 
the previous ADMET studies.
While both compounds (+)-13j and (+)-13l showed good pharmacological profiles, 
acceptable ADMET properties, and excellent brain penetration, their moderate hERG 
inhibition could be a concern for further development. A similarity analysis of their 
structures with known hERG inhibitors revealed that the scaffold embodied by this series of 
compounds matched one of the common structural templates known to cause hERG 
inhibition, which is comprised of a three-point pharmacophore containing an aromatic ring, 
an adjacent hydrogen-bond donor, and an ionizable N atom.25 However, the 5-fluoro 
containing compound 8 displayed no hERG inhibition in our previous studies.22 Thus, 
replacement of the chlorine atom by the less lipophilic fluorine atom at position 5 might lead 
to a decrease in hERG inhibition. Moreover, from the SAR data gleaned from the study of 
the 5-chloro bearing compounds, we concluded that some of the alkoxyl substitutions at 
position 2 on the benzene ring may provide advantages over the cyclopropylmethoxy group 
found in compounds 13e and 8 in terms of potency and selectivity. Therefore, the 
introduction of these substituents into the 5-fluoro containing scaffold might produce 
Cheng et al. Page 6













compounds with better potency and, more importantly, reduced hERG inhibitory activity. 
Four different substituents from Table 1 were chosen for this purpose, and the synthesis and 
evaluation of these compounds are described below.
Routes to the 5-fluoro compounds are depicted in Scheme 2. 5-Fluorophenol 14 was 
prepared and used as the starting material, the synthesis of which has been reported 
previously.22 Alkylation of 14 with 1-iodopropane, allyl bromide, or 3-chloro-2-
fluoropropene and a Mitsunobu reaction with 2-fluoroethanol provided the corresponding 
ethers 15a–15d in excellent yields (for details of the synthesis of 15a–15d, see Supporting 
Information, Table S2). These intermediates were separated using chiral preparative HPLC 
and then deprotected with HCl in diethyl ether to give both (−)- and (+)-enantiomers of 
compound 16a–16d. Similarly, absolute configurations of the enantiomers were assigned 
based on the measured optical rotations as described above.
Pharmacological profiles of the 5-fluoro compounds are summarized in Table 4. All (+)-
enantiomers had better efficacy than their (−)-enantiomers. However, a significant increase 
in potency at the 5-HT2C receptor was observed for these compounds compared to their 5-
chloro analogues, while excellent selectivity was maintained. Compound (+)-16a, bearing an 
n-propyl group, displayed an EC50 value of 11 nM at 5-HT2C and was 9-fold more potent 
than its 5-chloro analogue (+)-13b (EC50 = 103 nM). It showed a high degree of selectivity 
over 5-HT2B (EC50 = 1994 nM) and 5-HT2A (no activity). The allyl ether bearing derivative 
(+)-16b (EC50 = 4.2 nM) has a potency equal to that of lorcaserin. It showed much better 
selectivity over 5-HT2B (no activity observed), with an 89-fold selectivity against 5-HT2A 
(EC50 = 374 nM). The attachment of a fluorine atom to the allyl group, with the intent to 
enhance metabolic stability, led to (+)-16c that was slightly less potent at 5-HT2C (22 nM) 
but had an improved selectivity over 5-HT2A. The 2-fluoroethoxy bearing compound 
(+)-16d showed enhanced potency at 5-HT2C (EC50 = 3.4 nM), along with excellent 
functional selectivity over both 5-HT2B (no activity observed) and 5-HT2A (>100-fold 
selectivity).
To further investigate their drug-like character, compounds (+)-16b and (+)-16d were tested 
for both CYP and hERG inhibition. As shown in Table 5, improved CYP inhibition profiles 
were measured for (+)-16b and (+)-16d relative to compounds (+)-13h, (+)-13j, and (+)-13l. 
Less than 50% inhibition was observed at CYPs 3A4, 2D6, 2C9, and 2C19 for both 
compounds, while higher inhibition was observed at 2B6. As the 2B6 isoform is present in 
relatively low abundance in comparison to the other CYPs,26 these results are encouraging. 
In the hERG inhibition assay, although concentration-dependent inhibition was observed for 
(+)-16b and (+)-16d, both compounds afforded less than 50% inhibition at the highest 
concentration tested, which was 30 µM. These results suggest that the compounds may 
present a reasonable safety margin, as both compounds are active at the 5-HT2C receptor in 
the low nanomolar range.
Further pharmacological profiling was conducted for compounds (+)-16b and (+)-16d to 
investigate potential off-target activity. Binding studies were performed at 45 targets, 
including GPCRs, ion channels, neurotransmitter transporters, and sigma receptors, by the 
Psychoactive Drug Screening Program (PDSP). (+)-16b and (+)-16d were found to display 
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high affinity for the 5-HT2B and 5-HT2C receptors, with Ki values in the range of 30–50 nM. 
However, as already described, both compounds have been shown to be “functionally” 
selective for the 5-HT2C receptor. (+)-16b showed <1 µM Ki values at the 5-HT1A, 5-HT6, 
5-HT7, α2A, α2B, α2C, and dopamine D3 receptor, while (+)-16d showed binding at this 
same level at only α2A. None of the other targets analyzed were found to show any 
significant off-target affinity for these two compounds (Supporting Information, Table S3). 
Compared to the other known 5-HT2C agonists reported to date, compounds (+)-16b and 
(+)-16d thus represent attractive molecules in terms of both their 5-HT2C potency and 
selectivity.
In Vivo Test in a Schizophrenia-like Animal Model
The pharmacological profiles and ADMET properties of the best compounds from both the 
5-chloro and 5-fluoro series, (+)-13j, (+)-13l, (+)-16b, and (+)-16d, prompted their 
assessment in an animal model to explore their potential antipsychotic effects. One of the 
advantages of developing 5-HT2C agonists as antipsychotics is that they decrease levels of 
dopamine in limbic brain regions,27 which have been proven to mediate the antipsychotic 
effects of current antischizophrenia drugs. Meanwhile, agonism of the 5-HT2c receptor does 
not affect dopamine levels in the striatum, the region associated with extrapyramidal side 
effect of the “typical” antipsychotics.28 Moreover, the antiobesity effect of 5-HT2C agonists 
is well-known, exemplified by the approval of lorcaserin as an antiobesity drug. Thus, these 
agonists do not have the potential side effect of weight gain, which is observed with many 
antipsychotics which have properties of 5-HT2C antagonists or inverse agonists.29
Amphetamine-induced hyperactivity is a well-recognized rodent test used to assess the 
antipsychotic potential of a compound. To examine this possibility, compounds (+)-13j, 
(+)-13l, (+)-16b, and (+)-16d were tested in this model (details of the behavioral test are 
provided in the Experimental Section). Adult male C57BL/6J mice were given the vehicle 
(Veh) or one of the test compounds and were placed into the open field for 15 min. They 
were removed and administered the Veh or D-amphetamine (AMPH) and returned 
immediately to the open field for 105 min. As shown in Figure 3, D-amphetamine 
significantly increased locomotor activity from 16 to 120 min in the Veh–AMPH compared 
to the Veh–Veh group. Administration of each of the four compounds at the 10 or 20 mg/kg 
doses significantly reduced the AMPH-stimulated hyperlocomotion relative to the Veh–
AMPH group (p-values <0.035). Although responses to 10 and 20 mg/kg (+)-13l and 
(+)-16d were not differentiated by dose, compounds (+)-13j and (+)-16b dose dependently 
suppressed the hyperactivity such that locomotion at the 20 mg/kg doses was similar to that 
of the Veh–Veh group. Importantly, the 20 mg/kg dose of each the four compounds alone 
(20-Veh groups) had little influence on the spontaneous activity of the injected animals. The 
reduction in AMPH-stimulated hyperlocomotion, especially by compounds (+)-13j and 
(+)-16b, indicate their potential as antipsychotic agents and encourage further studies of 
other behaviors.
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Homology Modeling to Elucidate the Binding Mode of Key Compounds to the 5-HT2C 
Receptor
Following our SAR studies, we wanted to obtain some idea as to how (+)-16b might interact 
with the 5-HT2C receptor. Thus, the 5-HT2C primary sequence was retrieved from UniProt 
(P28335, 5HT2C_HUMAN), and two 5-HT2C homology models were generated. The first 
model (5-HT2C_inact) was obtained using the β2-adrenergic receptor (β2-AR) as a template in 
its inactive state (PDB: 2RH1), while the second model (5-HT2C_act) was generated by 
combining two templates, namely the resolved structure of 5-HT2B in a complex with 
ergotamine (PDB: 4IB4) and the β2-AR in its fully active state (PDB: 3SN6). This 5-HT2B-
ergotamine model was selected due to the fact that ergotamine has functional selectivity for 
5-HT2B, and thus the resolved structure does not represent a fully active state.30 By 
combining the two templates, the generated active model should benefit from the high 
homology in the orthosteric site between 5-HT2B and 5-HT2C while conserving features 
responsible for the fully activated state as taken from the β2-AR. The homology models were 
built by using Modeller9.12,31 and the best structures were selected for docking studies. 
Docking simulations were performed using PLANTS, which finds plausible ligand poses 
through ant colony optimization algorithms (ACO).32 (For details of the modeling study, see 
Supporting Information.)
The macroscopic view of compound (+)-16b binding to both the inactive and active 
conformations of the 5-HT2C and the magnified views of the binding sites are shown in 
Figure 4. As exemplified in Figure 4a, a significant difference was observed between the 
binding poses of compound (+)-16b with 5-HT2C_inactive and 5-HT2C_active, as the 
compound is inserted much deeper into a tighter niche when docking to 5-HT2C_active. As 
shown with the magnified view in Figure 4b, the computed complexes for the 5-HT2C_inact 
model are vastly stabilized by the ion pair between the ligand ammonium head and Asp134, 
a key contact reinforced by clear H-bonds with Ser138 and Tyr358 plus a charge transfer 
interaction with Trp130. By contrast, the remaining part of the ligand is seen to elicit only 
weak apolar contacts: (a) the cyclopropane ring approaches Ile131, (b) the phenyl ring is 
engaged in π-π stacking with Phe327, Trp355, and Tyr358, with the halogen atom 
approaching the indole nitrogen atom of Trp355, and (c) the alkenyl chain is stabilized by a 
possible π-π stacking interaction with Phe327.
A significantly different interaction pattern is observed when analyzing the computed 
complexes for the 5-HT2C_act model. As shown in Figure 4c, the interactions involving the 
ligand ammonium group are almost superimposable on those seen using the inactive model 
and involve Asp134, Ser138, and Tyr358, while the cyclopropane ring elicits apolar contacts 
with Val135 and Val185. The largest differences between the two 5-HT2C models are 
observed for the contacts that stabilize the remaining portion of the ligands because the 
phenyl ring is inserted into a tight niche lined by aromatic residues (i.e., Phe214, Trp324, 
Phe327, Phe328, and Tyr358) with which it can interact via extended π-π stacking 
interactions, while the ether bridge engages in two possible H-bonds with Ser219 and 
Asn331. Finally, the alkenyl tail also engages in a possible π-π stacking interaction with 
Phe214.
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Some differences were also observed when the binding pose of (+)-16b was compared to 
that found for (+)-13h, as is apparent from the overlay shown in Figure 4d. The interactions 
displayed by the ammonium group of (+)-13h are super-imposable to those of (+)-16b, but 
the positions of the benzene ring and the direction of the ether side chain are significantly 
different. The increase of steric hindrance upon changing the fluorine atom to a chlorine 
atom probably prevents the benzene ring from going deeper into the pocket, thus the ether 
side chain moves inside while the benzene ring is outside. The π-π stacking interactions 
within the tight niche lined by aromatic residues would therefore be anticipated to be weaker 
than those experienced by (+)-16b. This property might explain the fact that the potency of 
(+)-16b is about 15-fold higher than that of (+)-13h (4.2 vs 60 nM).
When the binding mode of compound (+)-16b is compared to that of lorcaserin, as shown in 
Figure 5, (+)-16b shares with lorcaserin the same key interactions that stabilize the 
ammonium group as well as the extended set of hydrophobic and stacking contacts, with the 
cyclopropane ring suitably replacing the carbon skeleton of the benzazepine ring. The major 
differences in the 5-HT2C_act model is that the polar contact, namely the likely H-bond with 
Asn331, is seen only with compound (+)-16b because of its ether oxygen atom, while the 
chlorine atom of lorcaserin engages Asn331 in possible hydrophobic contacts.
CONCLUSION
As our continuing efforts to optimize the 2-phenylcyclopro-pylmethylamine scaffold, new 
compounds bearing chlorine or fluorine substitutions at position 5 on the benzene ring were 
synthesized, and these modifications together with optimization of the ether substituent at 
position 2 led to compounds with good potency at the 5-HT2C receptor as well as improved 
selectivity against the 5-HT2B and 5-HT2A receptors. In turn, ADMET studies coupled with 
behavioral analysis in the amphetamine-stimulated hyperlocomotion model identified four 
compounds with good profiles as antipsychotic agents. Compound (+)-16b displayed an 
EC50 value of 4.2 nM at 5-HT2C, was 89-fold selective against 5-HT2A, and had no 
significant activity at 5-HT2B. It is one of the most potent and selective 5-HT2C agonists 
reported to date. At a dose of 20 mg/ kg, (+)-16b completely reversed amphetamine-induced 
hyperactivity in mice while showing no significant influence on the spontaneous activity of 
the tested animals. Molecular modeling studies were also performed to elucidate the possible 
binding poses of compound (+)-16b to the 5-HT2C receptor, using a homology model 
incorporating both the well-known β2-adrenergic receptor template and recently reported 5-
HT2B receptor.
The high potency and excellent selectivity profile of compound (+)-16b, together with its 
significant effects in an animal behavior study, strongly support the further evaluation of this 
compound as a chemical tool that can be used to elucidate the importance of the 5-HT2C 
receptors in normal human behaviors as well as in pathophysiological states. Further animal 
studies are being conducted to explore the use of this compound in the possible treatment of 
schizophrenia-like behaviors, and these studies will be reported separately.
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All chemicals and solvents were purchased from Sigma-Aldrich or Fisher Scientific and 
used without further purification. Microwave reactions were run in Biotage Initiator 
microwave synthesizer. Synthetic intermediates were purified by CombiFlash flash 
chromatography on 230–400 mesh silica gel. 1H and 13C NMR spectra were recorded on 
Bruker DPX-400 or AVANCE-400 spectrometer at 400 and 100 MHz, respectively. NMR 
chemical shifts were reported in δ (ppm) using residual solvent peaks as standard (CDCl3, 
7.26 ppm (1H), 77.23 ppm (13C); CD3OD, 3.31 ppm (1H), 49.15 ppm (13C); DMSO-d6, 2.50 
ppm (1H), 39.52 ppm (13C)). Mass spectra were measured in the ESI mode at an ionization 
potential of 70 eV with an LC-MS MSD (Hewlett-Packard). Purity of all final compounds 
(greater than 95%) was determined by analytical HPLC (ACE 3AQ C18 column (150 mm × 
4.6 mm, particle size 3 µM), 0.05% TFA in H2O/0.05% TFA in MeOH gradient eluting 
system). Optical rotation values were recorded on Autopol IV automatic polarimeter.
General Method A: Preparation of N-Boc-amines 12a–12n and 15a–15d
Intermediate 11 and 14 was treated with the Williamson ether synthesis or Mitsunobu 
reaction conditions as described in Scheme 1 and Scheme 2 (for detailed conditions, see 
Supporting Information, Tables S1 and S2). The reactions were monitored with TLC, and 
the workup was done with ethyl acetate and water. Crude product was purified with flash 
chromatography.
General Method B: Chiral Separation of N-Boc-amines 12a–12n and 15a–15d
The racemic intermediates were separated by chiral HPLC. Analytical conditions: RegisCell 
chiral column (25 cm × 4.6 mm, 10 µM), 1.5–15% EtOH in n-hexane as the fluent phase. 
Preparative conditions: RegisPack chiral column (25 cm × 21.1 mm, 10 µM), 3–7.5% EtOH 
in n-hexane as the eluting system (isocratic eluent, stacked injections, flow rate =18 mL/min, 
λ = 254 and 280 nm). (+)-12a–12n and (+)-15a–15d were isolated as the first-eluting peaks, 
with (−)-12a–12n and (−)-15a–15d as the second-eluting peaks, both after evaporation 
appeared as colorless oil or white solids. Optical purity of both enantiomers was determined 
on analysis HPLC after the separation, and a second separation was done when necessary to 
guarantee >90% ee optical purity.
General Method C: Deprotection of N-Boc-Amines to Afford HCl Salts (13a, 13b, 13e–13g, 
13i–13n, and 16a–16d)
N-Boc-Amines was dissolved in 2 M HCl (g) in diethyl ether (10 mL/mmol substrate) and 
stirred at room temperature for 24–48 h. The white solids formed were collected by 
filtration, washed with diethyl ether, and dried over vacuum to give the HCl salts as white 
solids.
General Method D: Deprotection of N-Boc-Amines to Afford TFA Salts (13c, 13d, and 13h)
To a solution of the N-Boc protected precursor (1 mmol) in CH2Cl2 (10 mL) was added to 
TFA (1 mL) at 0 °C under an argon atmosphere. The mixture was stirred at room 
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temperature for 1 h. The reaction mixture was concentrated and the residue was dissolved in 
water and methanol (ratio 4:1). The solution was filtered and then purified by Shidmadzu 
preparative LC using the following conditions: ACE 5AQ column (150 mm × 21.2 mm, 
particle size 5 µM). Method: 8–100% 0.05% TFA in MeOH/ 0.05% TFA in H2O, 30 min. 
Flow rate = 17 mL/min with monitoring at 254 and 280 nm wavelengths. After the solvent 
was evaporated, the residue was dissolved in distilled water (2–3 mL) and lyophilized to 
obtain the TFA salt.
Detailed synthetic procedures were described for compounds (−)-16b, (+)-16b, (−)-16d, and 
(+)-16d. Other compounds were prepared similarly with the general methods described 
above and the characterization data are provided in the Supporting Information.
tert-Butyl ((2-(2-(Allyloxy)-5-fluorophenyl)cyclopropyl)-methyl)carbamate (15b)
To a solution of compound 14 (282 mg, 1.0 mmol) in anhydrous DMF (2 mL) was added 
Cs2CO3 (489 mg, 1.5 mmol) and allyl bromide (242 mg, 2.0 mmol), and the mixture was 
heated in a microwave at 80 °C for 30 min. Water was added, and the mixture was extracted 
with ethyl acetate, the combined extracts were dried over Na2SO4, concentrated, and 
purified with flash chromatography (0–30% ethyl acetate in hexanes) to render the title 
compound as a colorless oil (250 mg, 78%). 1H NMR (400 MHz, CDCl3) δ 6.80 (dt, J = 8.8, 
3.2 Hz, 1H), 6.75 (dd, J = 8.8, 4.8 Hz, 1H), 6.61 (dd, J = 9.2, 2.8 Hz), 6.18–6.08 (m, 1H), 
5.42 (dd, J = 17.2, 1.6 Hz, 1H), 5.31 (dd, J = 10.4, 1.2 Hz, 1H), 5.08 (br, 1H), 4.61−4.57 (m, 
2H), 3.54−3.51 (m, 1H), 2.79−2.76 (m, 1H), 1.93−1.88 (m, 1H), 1.46 (s, 9H), 1.07−1.98 (m, 
2H), 0.88−0.82 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 157.3 (d, JCF = 236.9 Hz), 155.9, 
153.5, 133.3, 132.6 (d, JCF = 7.4 Hz), 118.1, 113.4 (d, JCF = 23.3 Hz), 112.5 (d, JCF = 22.5 
Hz), 112.4 (d, JCF = 8.4 Hz), 79.0, 69.8, 45.2, 28.5, 21.8, 17.0, 11.4. The racemate was 
separated with RegisPack chiral column (25 cm × 21.1 mm, 10 µM), 3.25% EtOH in n-
hexane as the eluting system (isocratic eluent, stacked injections, flow rate =18 mL/min, λ = 
254 and 280 nm). (+)-15b (92 mg, 97% ee) was separated as the first peaks and (−)-15b (78 
mg, 96% ee) as the second peaks. (+)-15b, [α]D20 +26.4 (c 0.5, CHCl3); (−)-15b, [α]D20 
−26.8 (c 0.5, CHCl3).
(−)-((1R,2R)-2-(2-(Allyloxy)-5-fluorophenyl)cyclopropyl)-methanamine Hydrochloride 
((−)-16b)
(+)-15b (80 mg, 0.25 mmol) was dissolved in 2 M HCl in diethyl ether (10 mL) and stirred 
at room temperature for 24 h. The precipitation was collected by filtration, washed with 
diethyl ether, and dried on vacuum to render the title compound as a white solid (48 mg, 
75%). 1H NMR (400 MHz, CD3OD) δ 6.93−6.86 (m, 2H), 6.73 (dd, J = 9.4, 3.2 Hz, 1H), 
6.17−6.10 (m, 1H), 5.45 (dd, J = 17.2, 1.6 Hz, 1H), 5.30 (dd, J = 10.4, 1.6 Hz, 1H), 4.60 (d, 
J = 5.6 Hz, 2H), 3.06 (dd, J = 13.2, 7.6 Hz, 1H), 2.98 (dd, J = 13.2, 4.2 Hz, 1H), 2.21−2.15 
(m, 1H), 1.34−1.30 (m, 1H), 1.14−1.02 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 158.8 (d, 
JCF = 225.7 Hz), 154.9, 135.0, 133.0(d, JCF = 7.4 Hz), 118.2, 114.3 (d, JCF = 17.8 Hz), 
114.1, 114.0 (d, JCF = 37.3 Hz), 71.0, 45.1, 19.7, 18.3, 13.7. HRMS (ESI) calculated for 
C13H17FNO ([M + H]+), 222.1294; found, 222.1273. [α]D20 −16.2 (c 0.4, MeOH).
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(−)-15b (60 mg, 0.19 mmol) was dissolved in 2 M HCl in diethyl ether (8 mL) and stirred at 
room temperature for 24 h. The precipitation was collected by filtration, washed with diethyl 
ether, and dried on vacuum to render the title compound as a white solid (32 mg, 66%). 1H 
NMR (400 MHz, CD3OD) δ 6.93−6.86 (m, 2H), 6.73 (dd, J = 9.6, 3.2 Hz, 1H), 6.17−6.10 
(m, 1H), 5.45 (dd, J = 17.2, 1.6 Hz, 1H), 5.30 (dd, J = 10.4, 1.6 Hz, 1H), 4.60 (d, J = 4.2 Hz, 
2H), 3.07 (dd, J = 12.8, 7.2 Hz, 1H), 2.98 (dd, J = 13.2, 5.6 Hz, 1H), 2.21−2.17 (m, 1H), 
1.35−1.31 (m, 1H), 1.14−1.04 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 158.8 (d, JCF = 
235.7 Hz), 155.0, 135.0, 133.0(d, JCF = 7.4 Hz), 118.2, 114.3 (d, JCF = 17.0 Hz), 114.1, 
114.0 (d, JCF = 36.1 Hz), 71.0, 45.1, 19.7, 18.3, 13.7. HRMS (ESI) calculated for 
C13H17FNO ([M + H]+), 222.1294; found, 222.1273. [ α]D20 +17.5 (c 0.2, MeOH).
tert-Butyl ((2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)-cyclopropyl)methyl)carbamate (15d)
To a solution of compound 14 (282 mg, 1.0 mmol), triphenylphosphine (787 mg, 3.0 mmol) 
and 2-fluoroethanol (192 mg, 3.0 mmol) in anhydrous THF (3 mL) was cooled at 0 °C and 
was added diethylazodicarboxylate (522 mg, 3.0 mmol) dropwise. The solution was then 
heated in microwave reactor at 60 °C for 40 min. The mixture was purified with flash 
chromatography (0–30% ethyl acetate in hexanes) after concentration to render 15d as a 
colorless oil (320 mg, 98%). 1H NMR (400 MHz, CDCl3) δ 6.82 (dt, J = 8.8, 2.8 Hz, 1H), 
6.77 (dd, J = 8.0, 4.8 Hz, 1H), 6.62 (dd, J = 9.2, 2.8 Hz, 1H), 5.02 (br, 1H), 4.88−4.73 (m, 
2H), 4.31−4.20 (m, 2H), 3.53−3.48 (m, 1H), 2.84−2.78 (m, 1H), 1.96−1.92 (m, 1H), 1.46 (s, 
9H), 1.10−1.05 (m, 1H), 1.02−0.98 (m, 1H), 0.88−0.82 (m, 1H). 13C NMR (100 MHz, 
CDCl3) δ 157.7 (d, JCF = 237.5 Hz), 155.9, 153.4, 133.2 (d, JCF = 7.4 Hz), 113.5 (d, JCF = 
23.4 Hz), 112.9 (d, JCF = 8.5 Hz), 112.6 (d, JCF = 22.7 Hz), 81.9 (d, JCF = 169.7 Hz), 79.1, 
68.5 (d, JCF = 20.2 Hz), 45.1, 28.5, 20.0, 16.8, 11.5. The racemate was separated with 
RegisPack chiral column (25 cm × 21.1 mm, 10 µM), 7.5% EtOH in n-hexane as the eluting 
system (isocratic eluent, stacked injections, flow rate = 18 mL/min, λ = 254 and 280 nm). 
(+)-15d (120 mg, > 99% ee) was separated as the first peaks and (−)-15d (110 mg, > 99% 




Compound (+)-15d (110 mg, 0.34 mmol) was dissolved in 2 M HCl in diethyl ether (8 mL) 
and stirred at room temperature for 24 h. The precipitation was collected by filtration, 
washed with diethyl ether, and dried on vacuum to render the title compound as a white solid 
(61 mg, 69%). 1H NMR (400 MHz, CD3OD) δ 6.97−6.86 (m, 2H), 6.76 (dd, J = 9.2, 2.8 Hz, 
1H), 4.87−4.75 (m, 2H), 4.32−4.20 (m, 2H), 3.04−3.00 (m, 2H), 2.19−2.15 (m, 1H), 
1.28−1.17 (m, 2H), 1.06−1.02 (m, 1H). 13C NMR (100 MHz, CD3OD) δ 159.0 (d, JCF = 
236.0 Hz), 155.0, 133.0 (d, JCF = 7.4 Hz), 114.6 (d, JCF = 24.0 Hz), 114.2 (d, JCF = 22.8 
Hz), 114.0 (d, JCF = 8.1 Hz), 83.6 (d, JCF = 166.6 Hz), 69.7 (d, JCF = 18.9 Hz), 45.0, 20.0, 
18.3, 13.0. HRMS (ESI) calculated for C12H16F2NO ([M + H]+), 228.1200; found, 
228.1179. [α]D20 −3.3 (c 0.3, MeOH).
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This compound was prepared from (−)-15d as described for (−)-16d as a white solid. 1H 
NMR (400 MHz, CD3OD) δ 6.97−6.88 (m, 2H), 6.76 (dd, J = 9.6, 3.2 Hz, 1H), 4.87−4.74 
(m, 2H), 4.32−4.22 (m, 2H), 3.03 (d, J = 7.6 Hz, 2H), 2.20−2.15 (m, 1H), 1.28−1.25 (m, 
1H), 1.22−1.17 (m, 1H), 1.07−1.02 (m, 1H). 13C NMR (100 MHz, CD3OD) δ 159.0 (d, JCF 
= 236.2 Hz), 155.0, 133.1 (d, JCF = 7.3 Hz), 114.6 (d, JCF = 24.0 Hz), 114.2 (d, JCF = 17.5 
Hz), 114.1 (d, JCF = 3.1 Hz), 83.6 (d, JCF = 166.6 Hz), 69.7 (d, JCF = 19.8 Hz), 45.0, 20.0, 
18.3, 13.1. HRMS (ESI) calculated for C12H16F2NO ([M + H]+), 228.1200; found, 
228.1173. [α]D20 +3.6 (c 0.3, MeOH).
Calcium Flux Assay
Flp-In-293 cells stably expressing the human 5-HT2A, 5-HT2B, or 5-HT2C-INI were grown 
for 24–48 h in DMEM containing 10% dialyzed FBS before seeding. Cells were plated into 
Poly-L-Lys-coated 384-well black clear bottom cell culture plates in DMEM with 1% 
dialyzed FBS at a density of 12000 cells per 50 µL per well for 24 h. Preceding the 
experiment, culture medium was removed and 20 µL of assay buffer (20 mM Hepes, pH 
7.40, Hanks’ balanced salt solution, 2.5 mM probenecid, 1× FLIPR calcium dye) was added 
and cells were incubated at 37 °C for 1 h. Serial dilutions of each tested drug were prepared 
at 3× final concentration and transferred to 384-well plates. Each drug plate contained 5-HT 
and lorcaserin in serial dilutions for internal reference. Cell and drug plates were placed in a 
FLIPRTETRA fluorescence imaging plate reader (Molecular Dynamics). The FLIPRTETRA 
was programmed to read baseline for 10 s (1 read/s) and then add 10 µL of drug/well and 
read for an additional 120 s. Fluorescence was normalized to the average of the baseline 
(first 10 reads), and the maximum fold increase peak was determined for each drug and 
controls (5-HT and lorcaserin). Data were plotted as a function of drug concentration and 
were normalized compared to the internal 5-HT reference for each plate recorded. 
Normalized data were regressed using a sigmoidal dose–response function. Data of two 
independent experiments (n = 2) conducted in quadruplicate are presented. Analyses were 
performed using the software from GraphPad Prism 6.0. 5-HT2C EC50 confidence intervals 
(5-HT, 0.16–0.26 nM; lorcaserin, 3.1–3.9 nM), Emax Std Error (5-HT, 100% ± 1.04; 
lorcaserin, 99% ± 0.75); 5-HT2B EC50 confidence intervals (5-HT, 0.66–1.17 nM; lorcaserin, 
429–527 nM), Emax Std Error (5-HT, 100% ± 1.69; lorcaserin, 92% ± 3.01); 5-HT2A EC50 
confidence intervals (5-HT, 1.60–2.16 nM; lorcaserin, 275–329 nM), Emax Std Error (5-HT, 
100% ± 1.03; lorcaserin, 68% ± 0.83).
Open Field Activity
Adult male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were injected (ip) with 
the vehicle (Veh, 0.9% saline from Butler Schein Animal Health, Dublin, Ohio) or different 
doses of compounds (+)-13j, (+)-13l, (+)-16b, or (+)-16d (compounds were dissolved in 
0.9% saline and injected intraperitoneally at 5 mL/kg) and placed into the open field for 15 
min. The mice were removed and administered (ip) the Veh or 3 mg/kg amphetamine 
(AMPH; Sigma-Aldrich, St. Louis, MO) and returned to the open field for 105 min. 
Locomotor activity was monitored as distance traveled in an automated Omnitech Digiscan 
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apparatus using VersaMax software (AccuScan Instruments, Columbus, OH). The results are 
presented as means and standard errors of the mean using SPSS software (IBM, Armonk, 
NY). The data from the 0–15 min interval were analyzed by three-way ANOVA for 
condition (vehicle and AMPH), treatment (compounds (+)-13j, (+)-13l, (+)-16b, and 
(+)-16d), dose (10 or 20 mg/kg), and dose nested in treatment (to reflect the different doses 
tested per compound). Because activities among the groups at the 0- 15 min interval were 
significantly different, a RMANOVA was run with a sequential sum of squares (to control 
for the group differences at 0–15 min) for test interval (0–15 and 16–120 min), condition, 
treatment, dose, and dose (treatment) to control for these group differences. All posthoc 
analyses were by Bonferroni corrected pairwise comparisons where a p < 0.05 was 
considered significant.
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Refer to Web version on PubMed Central for supplementary material.
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Selective 5-HT2C agonists based on 2-phenylcyclopropylme-thylamine scaffold.
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Cumulative locomotor activity following injection of the vehicle (Veh) or 3 mg/kg D-
amphetamine (AMPH). AMPH-stimulated locomotor activity in the Veh–AMPH group was 
higher than that in all other groups tested. Locomotion in the Veh–Veh group was similar to 
that in the (+)-13j–Veh, (+)-13l–Veh, (+)-16b–Veh, and (+)-16d–Veh groups (i.e., 20-Veh 
groups). Both 10 and 20 mg/kg of each of the four compounds decreased the AMPH-
stimulated hyperlocomotion, with 20 mg/kg (+)-13j and (+)-16b being the most efficacious. 
N = 8–16 mice/group; *, p < 0.035, from the Veh–AMPH group.
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Predicted binding poses of compound (+)-16b in 5-HT2C. (a) Docking poses of compound 
(+)-16b in the 7-transmembrane domain (7TMD) of the 5-HT2C_inactive (compound shown 
in light yellow, protein shown in gray) and 5-HT2C_active (compound shown in orange, 
protein shown in green) conformations. (b) Magnified view of binding sites of compound 
(+)-16b in 5-HT2C_inactive. (c) Magnified view of binding sites of compound (+)-16b in 5-
HT2C_active. (d) Overlay of compound (+)-16b (orange) with (+)-13h (sky blue) in the 
binding pocket.
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Overlay of compound (+)-16b (orange) with lorcaserin (pink) in the binding pocket of 5-
HT2C_active.
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Synthesis of 5-Chloro Compoundsa
aReagents and conditions: (a) Williamson ether synthesis with R1X or Mitsunobu reaction 
with appropriate alcohols; (b) chiral prep-HPLC separation; (c) 13c, 13d, 13f, 13h, and 13i, 
TFA/CH2Cl2, rt, 1h; 13a, 13b, 13e, 13g, 13j–13n, 2 M HCl in diethyl ether, rt, 24–48 h.
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Synthesis of 5-Fluoro Compoundsa
aReagents and conditions: (a) Williamson ether synthesis with R1X or Mitsunobu reaction 
with appropriate alcohols; (b) chiral prep-HPLC separation; (c) 2 M HCl in diethyl ether, rt, 
24 h, 64–80%.
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Table 2
In Vitro ADMET Data for Compounds (+)-13h, (+)-13j, and (+)-13la
compd (+)-13h (+)-13j (+)-13l
Caco-2 permeability (pH
7.4, × 10−6 cm/s)
A–B 35.6 38.3 35.5
B–A 9.8 10.8 17.5
microsomal stability (%) human 52 80 95
mouse 60 62 74
human PPB at 10 µM (%) 75 68 57
CYP inhibition at 10 µM
(%)
3A 27 27 22
2D6 91 80 79
2C9 56 51 33
2C19 32 33 21
2B6 86 77 58
hERG IC50 (µM) 0.27 3.98 2.00
Ames fluctuation test negative negative negative
aThis study was conducted at Cerep, Inc. (Redmond, USA); microsomal stability is presented as % compound remaining after 1 h incubation with 
human/mouse liver microsomes; the CYP inhibition assays were performed using human liver microsomes; midazolam, dextromethorphan, 
diclofenac, omeprazole, and bupropion were used as test substrates for the 3A, 2D6, 2C9, 2C19, and 2B6 isoforms, respectively; hERG inhibition 
was tested on CHO cells using the automated patch-clamp method; the Ames fluctuation test was performed with the TA98, TA100, TA1535, and 
TA1537 strains, with/without S9, at concentrations of 10, 50, and 100 µM.
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Table 3












(+)-13j 0.5 17460 1445 12.1
2 14670 903 16.2
(+)-13l 0.5 12795 1200 10.7
2 13350 874 15.3
aCD1 mice were administrated a single dose of both compounds (10 mg/kg, ip, formulation in pure water).
bDensity of mouse brain tissue was calculated as 1 g/mL.
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Table 4





- 5-HT 0.21 (100%) 0.92 (100%) 1.88(100%) - -
- lorcaserin 3.6 (99%) 478 (92%) 302 (68%) - -
(−)-16a 296 (80%) 735(11%) NA
2.35 0.24
(+)-16a 11 (88%) 1994(33%) 1025 (15%)
(−)-16b 157(87%) NA 697 (56%)
2.50 −0.02
(+)-16b 4.2 (87%) NA 374 (56%)
(−)-16c 985 (62%) NA NA
2.48 0.23
(+)-16c 22 (91%) NA 1666(17%)
(−)-16d 514(77%) NA 2994 (20%)
2.94 0.23
(+)-16d 3.4 (89%) NA 359 (76%)
aFunctional data were acquired with recombinant, stably expressed human 5-HT receptors in the HEK-293 cell line, using a fluorescence imaging 
plate reader (FLIPR) assay; “NA”, no activity at 10 µM.
bCLogP and LogBB values were calculated for the free bases using the ACD Percepta program.
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Table 5
CYP and hERG Inhibition Data for Compounds (+)-16b and (+)-16d
assay (+)-16b (+)-16d





hERG inhibitionb (%) 0.37 µM 6.4 6.0
1.1 µM 8.7 11
3.3 µM 18 15
10 µM 29 25
30 µM 45 35
aCYP inhibition test was performed using human liver microsomes; midazolam, dextromethorphan, tolbutamide, (S)-mephenytoin, and bupropion 
were used as test substrates for the 3A4, 2D6, 2C9, 2C19, and 2B6 isoforms, respectively.
bhERG inhibition was tested on CHO cells using the automated patch-clamp method.
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